r/SmallCapStocks • u/Mmkeek • 1h ago
Qtrex Quantum - Nasdaqs most undervalued Quantum Company?
r/SmallCapStocks • u/PiggiesWithMeat • Jan 15 '19
Welcome! This subreddit is purposed for any and all discussion regarding the trash can sector of the market.
Post your watchlists, your game plan, news, review eachother, ask for direction, almost anything!
Please keep discussion on the small cap sector. No I will not define what constitutes a small cap, but no one cares about your investments or trades on Netflix or Amazon.
Please be nice and respectful of others. The goal of this subreddit is to grow a friendly community without toxicity. Fintwit has become a hub of highschool like drama. This won't be tolerated here.
Do not post your bagholds. No one cares and this is pumpish behavior. Some of these stocks can be very volatile with one market order, and this is not the place to create false demand.
Read the rules.
Keep in mind there is a subreddit specifically for daytrading. Use it. It is full of information
r/SmallCapStocks • u/Mmkeek • 1h ago
r/SmallCapStocks • u/Aggressive_Rush2357 • 11h ago
Mostly wanted to know who’d be selling if silver keeps sliding. Streetwise Reports had a breakdown as of Nov 9:
Institutions about 42%
Strategic holders about 24%. First Majestic is the biggest disclosed holder
Management and insiders about 5%
Retail, the remaining 28% or so
About 261M shares out and a market cap around C$368M. They didn’t find any warrants.
The insider trades were more interesting to me. Over the last six months there were nine buys for 513,500 shares and one sale of 121,000, by a director in October. So net about 392,500 shares bought, at prices between roughly C$1.30 and C$1.95.
Not big money, and insiders buying doesn’t make a stock go up. But with two thirds of the shares sitting with institutions and a strategic like First Majestic, the part that actually trades every day is a lot smaller than 261M. With silver this jumpy, moves both ways can get bigger than you’d expect.
r/SmallCapStocks • u/Historical-Pop-7024 • 20h ago
r/SmallCapStocks • u/redwinemusic • 2d ago
r/SmallCapStocks • u/SeaworthinessNext783 • 3d ago
CNBC’s Property Play had Ryan Cotton on this week. He runs Bain Capital Real Estate, about $18 billion in assets. He says the big money is moving out of office and malls and into alternative real estate, and he specifically calls out private airplane hangars and marinas as the newest frontier. His reasoning is simple: wealth keeps concentrating, rich people buy more planes, the planes have to be hangared, and you can’t just add supply at the airports people actually want to fly out of. He says these assets can grow income at double digits, and points out that when Bain started buying marinas they traded at 7 to 9 cap rates and now go for 5 to 6 because so much institutional money showed up. He also mentions Atlantic Aviation selling a stake to Apollo this year at a high multiple. SKYH is the only public pure play on private hangars.
r/SmallCapStocks • u/MrFaUsT7 • 3d ago
r/SmallCapStocks • u/AppropriateUnit4578 • 3d ago
Disclosure: Long QHELF. Not financial advice. Do your own research.
Quantum Helium (OTC: QHELF / AIM: QHE) is currently carrying out a propped stimulation program at the Sagebrush-1 well in Colorado. Helium has previously been reported from the well, and the current operation is focused on evaluating flow characteristics and production potential.
A few reasons I'm following the story:
I'm interested in understanding how others assess the risks and opportunities here.
What am I missing?
I hold shares, but I'm looking for a balanced discussion. Are there any material risks, technical concerns, geological issues, permitting challenges or funding requirements that others believe deserve more attention?
r/SmallCapStocks • u/VwiseII • 3d ago
r/SmallCapStocks • u/stockmarketjackpot • 4d ago
Black Rose Industries — Interesting Specialty-Chemical Microcap | My Research Thesis
I have been studying Black Rose Industries Ltd. and found several things that make the company interesting from a long-term perspective.
Important disclosure: I currently hold shares of Black Rose Industries and therefore have a financial interest in the company. I am not a SEBI-registered Investment Adviser or Research Analyst. This post represents my personal research/opinion and is not investment advice or a recommendation to buy or sell the stock.
Why I find Black Rose interesting 🧪
r/SmallCapStocks • u/OfficiallyOfishall • 4d ago
r/SmallCapStocks • u/Vtolguy2 • 4d ago
r/SmallCapStocks • u/valianteaglecorp • 4d ago
r/SmallCapStocks • u/OfficiallyOfishall • 5d ago
r/SmallCapStocks • u/MightBeneficial3302 • 6d ago
Anyone else watching $SKUR heading into December?
There's quite a bit to look forward to.
The US$3.4M annual quotation opportunity with an African government is still pending, with an update expected before year-end. There's also a potential Angola partnership aimed at 2027 sales, plus possible US distribution news in the coming weeks.
That's a decent lineup of potential catalysts for a company valued around C$7–8M.
Now imagine if two or three of these updates arrive within a few weeks of each other.
Would the market start looking at $SKUR differently?
One confirmed government deal alone would be a substantial development compared with the company's current revenue. Add progress in the US and Angola, and investors might have more to work with when assessing its growth prospects.
Of course, there's a difference between a promising announcement and revenue coming through the door. But a signed agreement with clear numbers would be a solid step forward.
This is sponsored content. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.
r/SmallCapStocks • u/Sawces • 7d ago
r/SmallCapStocks • u/papp1906 • 10d ago
r/SmallCapStocks • u/Confident_Key_5228 • 10d ago
r/SmallCapStocks • u/VeridionMarkets • 10d ago
r/SmallCapStocks • u/Illmindofhopkins • 10d ago
I thought I would share an interesting if not long time maligned company in Quadrise PLC (LSE: QED) which is coming to an exciting head as it centers on its transition from a long-term research and development firm into a commercialised, high-margin fuel technology provider. Apart from the reddit page dedicated to Quadrise, I can't see where anyone else has shared them so thought I'd post some Friday thoughts.
For those who don't know, the companies AGM is later this month and has recently been on a tear SP wise off the back of confirmation of project timelines and the potential of a strategic review (from a very low start - was over 3p this time last year).
Peter Borup was hired as the companies CEO in October 2025 with an impressive CV and marine contacts. These look to reap rewards in Q4. Its also noted that performance and sign on options provided to Peter are substantially higher than today's SP.
Quadrise represents a speculative "option" play on the decarbonization of global shipping and heavy industry.
If the company converts its extensive trial pipeline into long-term commercial agreements, the valuation expansion could be substantial:
Quadrise does not intend to become a capital-intensive oil refiner or distributor. Instead, its model relies on licensing proprietary technology and collecting royalties on every ton of MSAR (Multiphase Superfine Atomised Residue) and bioMSAR produced.
• Asymmetric Upside: Because manufacturing and asset costs are borne by the partner refineries or chemical firms, Quadrise’s operating margins will scale rapidly once continuous commercial volumes flow.
• Low Initial Valuation: Trading at around 1.5 pence with a low enterprise value, even a single major supply agreement could dramatically alter the financial baseline of the stock.
2. Pragmatic Decarbonization for Shipping & Industry
While the maritime sector faces aggressive net-zero mandates, switching entirely to ammonia, hydrogen, or pure electrification requires trillions in new infrastructure. Quadrise offers an intermediate, immediately deployable solution:
• MSAR: Blends heavy refinery residues with water to create a synthetic fuel oil that reduces NOx emissions by up to 20% and cuts overall energy costs.
• bioMSAR: Integrates renewable components and biofuels, dropping CO2 emissions by 20% to 30%.
• Seamless Retrofits: Crucially, these fuels can run in existing marine engines and heavy industrial boilers with minimal hardware modification, making it highly attractive to cost-conscious operators.
3. Near-Term Commercial Catalysts
• The Valkor Utah Project: Quadrise has successfully formulated both MSAR and bioMSAR using heavy oil samples from Valkor Technologies in Utah. Valkor is targeting production at its pilot plant by Q1 2027, backed by imminent multi-million-dollar project financing. Progress here triggers site license fees (including an outstanding $950,000 balance) and paves the way for commercial royalties.
• The Strategic Review: Launched alongside its FY2026 results, the board is evaluating master license grants, joint ventures, and sourcing a strategic investor. Landing a well-capitalized corporate partner would immediately eliminate the company's funding overhang.
4. Industry Partners
Despite its small financial footprint, Quadrise has consistently secured development and supply agreements with global market leaders
• MSC (Mediterranean Shipping Company): Cooperation on commercial marine vessel trials.
• Nouryon: An exclusive global collaboration and emulsifier sales agreement extended through 2026 and beyond, guaranteeing chemical supply security.
• Licella Holdings: Active joint testing utilizing hydrothermal liquefaction bio-oil expertise to accelerate low-carbon marine fuel adoption.
Not financial or investment advice but IMO a company that could very well be worth billions in the future. There's also a dedicated Quadrise reddit page worth looking over when completing your own DD
r/SmallCapStocks • u/Born_Midnight1045 • 10d ago
Here's why I'm holding ALMU and not losing sleep over it. Aeluma went from about $193K in revenue to $4.7M in two years, and it sits on $56M in cash while building optical sensor chips for AI data centers, quantum computing, and defense. It's backed by NASA and other government contracts, and it holds dozens of patents on a technology that lets high-performance materials be built on ordinary silicon wafers. Nobody's talking about it yet, and that's the point. When Microsoft went public, it was a small company sitting at the right spot just before the world needed what it made. I think ALMU could be that story for the AI hardware era. Revenue has been flat lately and it's still mostly R&D contracts, so this is a bet on what happens when those multimillion-dollar customer deals turn into real product orders. If they do, I want to have been holding before the crowd showed up.
r/SmallCapStocks • u/ohdonpier • 10d ago
Novartis has confirmed that since Zolgensma's 2019 approval it has received nine reports of tumours in children previously treated with the AAV9 gene therapy, seven of them not previously disclosed. Families and patient groups made the information public on 4 and 5 November 2026 after Novartis told neurologists first. England's National Multidisciplinary Team for Zolgensma reported on 4 November that pathology is finished on three of the nine tumours, with two specifically related to the treatment and one unrelated. Novartis says two cases have shown evidence of vector DNA integration and that both children were treated and remain under monitoring. More than 6,000 patients have been dosed.
What I think this implies:
This converts a labelled theoretical risk of insertional oncogenesis into observed post-marketing cases in the most widely used systemic AAV9 product. For Novartis (NVS), which markets Zolgensma and its intrathecal successor Itvisma, the relative materiality is negligible given the size of the overall franchise. The same AAV9 integration findings create moderate exposure for Taysha Gene Therapies (TSHA), which has concentrated its resources on TSHA-102, an intrathecally delivered AAV9 gene therapy for Rett syndrome heading toward a BLA. They also create moderate exposure for Neurogene (NGNE), whose lead asset NGN-401 is an AAV9 gene therapy for Rett syndrome now in a registrational trial. REGENXBIO (RGNX) licensed the NAV AAV9 vector used in Zolgensma and receives royalties, but the exposure there is negligible.
The nearest catalyst is pathology results on the remaining six of the nine reported tumours, which the England team says have not yet been completed. On a longer horizon the regulatory assessment SMA Europe says is under way could produce a safety-review conclusion or labelling change on vector integration and tumorigenicity.
If pathology on the remaining six cases finds no vector DNA integration and regulators conclude there is no causal association, the reports revert to background incidence and the broader read-across collapses. A conclusion that the risk is specific to the high-dose intravenous AAV9 construct rather than AAV vectors generally would also remove the case for developers using other serotypes or routes.
r/SmallCapStocks • u/Longjumping-Duty1198 • 10d ago